Table 1.
Characteristics of 25 MSM PWH With Human Monkeypox Virus Infection
| Patients, No. (%) | |
|---|---|
| Agea | 39.5 (33–46) |
| Years of HIV infectiona | 11 (9–13) |
| Prior AIDS | 3 (12) |
| Years on ARTa | 9 (6–115) |
| Current ART regimen | |
| TAF/FTC/BIC | 17 (68) |
| DTG/3TC | 5 (20) |
| TAF/FTC//RPV | 2 (8) |
| DRV/c + DTG | 1 (4) |
| CD4 count, cells/mLa | 630 (4815–923) |
| Reported clinical features | |
| Rash or skin lesions | 25 (100) |
| Fever | 14 (56) |
| General malaise | 12 (48) |
| Lymphadenopathy | 21 (84) |
| Pharyngitis | 5 (20) |
| Myalgias | 4 (16) |
| Proctitis or anorectal pain | 13 (52) |
| Distribution of lesions | |
| Genital/perianal | 14 (56) |
| Trunk | 12 (48) |
| Face | 10 (40) |
| Arms | 10 (40) |
| Hands | 5 (20) |
| Oral | 3 (12) |
| Monkeypox viral DNA detected, positive/total No. (%) | |
| Skin/genital skin | 20/22 (91) |
| Rectum | 9/10 (90) |
| Oral mucosa | 3/3 (100) |
| Pharynx | 3/4 (75) |
| Concomitant STIb | 6 (24) |
| Chlamydia trachomatis | 4 |
| Neisseria gonorrhoeae | 2 |
| Lymphogranuloma venereum | 1 |
| HSV-1 | 1 |
| Syphilis | 1 |
| Documented smallpox vaccination | |
| Yes | 5 (20) |
| No | 9 (36) |
| Unknown | 11 (44) |
| Duration of lesions, da | 8 (6.5–11) |
Abbreviations: ART, antiretroviral treatment; DRV/c + DTG, darunavir/cobicistat plus dolutegravir; DTG/3TC, dolutegravir plus lamivudine; HSV-1, herpes simplex virus 1; LGV, lymphogranuloma venereum; MSM, men who have sex with men; PWH, people with HIV; STI, sexually transmitted infection; TAF/FTC/BIC, tenofovir alafenamide plus emtricitabine plus bictegravir; TAF/FTC/RPV, tenofovir alafenamide plus emtricitabine plus rilpivirine.
a
Median (interquartile range).
b
Coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in 2 patients and Chlamydia trachomatis alone in 2 patients (1 resulted LGV).